BMPR2 Antibody (YA4754)

BMPR2 (bone morphogenetic protein receptor type 2) encodes a type II serine/threonine kinase receptor within the BMP/TGF-β signaling pathway, where it functions as a critical regulator of cellular signaling required for vascular homeostasis and tissue-specific growth control^[1][2]. Mechanistically, BMPR2-mediated signaling maintains pulmonary vascular integrity, and disruption of this pathway leads to imbalance of BMP/TGF-β signaling with downstream effects on cellular proliferation, apoptosis resistance, inflammatory activation, and metabolic reprogramming^[2][1]. Disease relevance is most strongly established in pulmonary arterial hypertension (PAH), in which heterozygous or loss-of-function BMPR2 mutations represent the major genetic cause of heritable disease and are also detected in a subset of idiopathic cases^[2][3][4]. Experimental and clinical studies demonstrate that reduced BMPR2 expression or dysfunctional signaling contributes to pulmonary vascular remodeling and disease progression, supporting a central pathogenic role for the receptor in pulmonary vascular biology^[2][3][5]. Compared with related components of the BMP signaling network, BMPR2 is distinguished by its role as the principal type II receptor whose genetic disruption is most consistently associated with hereditary PAH, making it a key molecular entry point for mechanistic and translational studies^[2][4]. For experimental applications, therapeutic strategies that restore or enhance BMPR2 signaling, including gene delivery approaches and pharmacological activation of the pathway, have shown potential to attenuate pulmonary hypertension phenotypes and are widely used to investigate BMPR2-directed disease mechanisms and intervention strategies^[5][6].